FASN and metabolic dysfunction-associated steatohepatitis: Palmitoylation of endothelial nitric oxide synthase (eNOS) decreases nitric oxide production, while insulin resistance and fatty acid synthase downregulation [28, 46], implying a reduction of de novo lipogenesis mediated by MyD88 palmitoylation as observed in non-alcoholic steatohepatitis treatment with caffeine, which could justify the differences in body weight in males [44].